共 31 条
- [21] Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after primingPEDIATRIC RESEARCH, 2024,Peterson, JamesGalarza, KatherineBchir, SihamZocchetti, CelineBertrand-Gerentes, IsabelleZambrano, Betzana
- [22] Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled studyBMC Infectious Diseases, 13Charissa Borja-TaboraCecilia MontalbanZiad A MemishMarie Van der WielenVeronique BiancoDominique BoutriauJacqueline Miller
- [23] Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled studyBMC INFECTIOUS DISEASES, 2013, 13Borja-Tabora, CharissaMontalban, CeciliaMemish, Ziad A.Van der Wielen, MarieBianco, VeroniqueBoutriau, DominiqueMiller, Jacqueline
- [24] Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccineHUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1272 - 1279Quiambao, BeatrizPeyrani, PaulaLi, PingCutler, Mark W.Van Der Wielen, MariePerez, John L.Webber, Chris
- [25] Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized studyVACCINE, 2018, 36 (31) : 4750 - 4758Rivera, LuisSchwarz, Tino F.Kim, Kyung-HyoKim, Yun-KyungBehre, UlrichCha, Sung-HoJo, Dae SunLee, JacobLee, Jin-SooCheuvart, BrigitteJastorff, ArchanaVan der Wielen, Marie
- [26] Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled TrialDrugs & Aging, 2013, 30 : 309 - 319Ghassan DbaiboNabil El-AyoubiSoha GhanemFarah HajarVeronique BiancoJacqueline M. MillerNarcisa Mesaros
- [27] Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled TrialDRUGS & AGING, 2013, 30 (05) : 309 - 319Dbaibo, GhassanEl-Ayoubi, NabilGhanem, SohaHajar, FarahBianco, VeroniqueMiller, Jacqueline M.Mesaros, Narcisa
- [28] Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trialBMC Infectious Diseases, 15Charissa Fay Corazon Borja-TaboraCecilia MontalbanZiad A. MemishDominique BoutriauDevayani KolheJacqueline M. MillerMarie Van der Wielen
- [29] Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trialBMC INFECTIOUS DISEASES, 2015, 15Corazon Borja-Tabora, Charissa FayMontalban, CeciliaMemish, Ziad A.Boutriau, DominiqueKolhe, DevayaniMiller, Jacqueline M.Van der Wielen, Marie
- [30] Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2-or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 monthsVACCINE, 2021, 39 (32) : 4545 - 4554Ostergaard, LarsVesikari, TimoSenders, Shelly D.Flodmark, Carl-ErikKosina, PavelJiang, Han-QingMaguire, Jason D.Absalon, JudithJansen, Kathrin U.Harris, Shannon L.Maansson, RogerBalmer, PaulBeeslaar, JohannesPerez, John L.